Lenvatinib, also known as E7080, is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
Naito, Toshihiko; Yoshizawa, Kazuhiro. Preparation of urea moiety-containing quinolinecarboxamide derivatives. WO 2005044788. (Assignee Eisai Co., Ltd., Japan)
Oruganti, Srinivas; Kandagatla, Bhaskar. Improved process for the preparation of lenvatinib using dimethylformamide as a solvent. IN 201641011188. (Assignee Dr. Reddy's Laboratories Limited, India)
Shah, Dharmesh Mahendrabhai; Wader, Guruprasad Ramchandra; Mehta, Tushar Bharatkumar; Chavda, Rajendra Gokalbhai; Kathrotiya, Harshad Ghanshyambhai; Patel, Arpit Kiritbhai. Improved process for the preparation of lenvatinib. WO 2019016664. (Assignee BDR Lifesciences Private Limited, India)
Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Ken-Ichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru. Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis. US 7253286. (Assignee Eisai Co., Ltd, Japan)
He, Peng; Wang, Xuechao; Deng, Ta; He, Qian. Method for preparing lenvatinib intermediate. CN 108997214. (Assignee Chengdu Diao Pharmaceutical Group Co., Ltd., Peop. Rep. China)
Zheng, Shiyang; Zhi, Yonggang. Method for preparation of lenvatinib. CN 108658859. (Assignee Chengdu Organic Chemicals Co., Ltd., Chinese Academy of Sciences, Peop. Rep. China)
Ge, Wenlei; Gao, Junlong; Liu, Kai; Guo, Dapeng. Process for preparation of lenvatinib impurity 4,4'-(((carbonylbis(azanediyl))bis(3-chloro-4,1-phenylene))bis(oxy))bis(7-methoxyquinoline-6-carboxamide) or its salt. CN 108299294. (Assignee Jiangsu Hengrui Medicine Co., Ltd., Peop. Rep. China)
Dong, Lichun; Hu, Geng; Li, Qi; Liu, Dianqing; Wang, Haoyuan. Synthesis method of anticancer drug lenvatinib. CN 107629001. (Assignee Chongqing University, Peop. Rep. China)
Jia, Huijuan; Chen, Yan; Zhang, Fan; He, Xuemin. Synthesis method of lenvatinib mesylate impurities. CN 107266363. (Assignee Hangzhou Huadong Medicine Group New Drug Research Institute Co., Ltd., Peop. Rep. China; Hangzhou Zhuyangxin Pharmaceutical Co., Ltd.; Zhejiang Huayi Pharmaceutical Co., Ltd.)
Nakamura, Taiju; Abe, Taichi; Miyashita, Yusuke; Kuroda, Hirofumi; Ayata, Yusuke; Akao, Atsushi. Highly pure quinoline derivative and method for the preparation thereof. WO 2016031841. (Assignee Eisai R&D Management Co., Ltd., Japan)
